Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome

  • Sci Adv. 2024 Feb 2;10(5):eadj7813. doi: 10.1126/sciadv.adj7813.
Wei Wang  1 Jinyou Li  2 Siyuan Cui  3 Jiayu Li  1 Xianlong Ye  4 Zhe Wang  1 Tingting Zhang  1 Xuan Jiang  1 Yulin Kong  1 Xin Chen  3 Yong Q Chen  1 Shenglong Zhu  1  3
Affiliations
  • 1. Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China.
  • 2. Affiliated Hospital of Jiangnan University, Wuxi 214122, China.
  • 3. Jiangnan University Medical Center, Wuxi 214002, China.
  • 4. Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China.
Abstract

Metabolic syndrome (MetS) is closely associated with an increased risk of dementia and cognitive impairment, and a complex interaction of genetic and environmental dietary factors may be implicated. Free Fatty Acid Receptor 4 (Ffar4) may bridge the genetic and dietary aspects of MetS development. However, the role of Ffar4 in MetS-related cognitive dysfunction is unclear. In this study, we found that Ffar4 expression is down-regulated in MetS mice and MetS patients with cognitive impairment. Conventional and microglial conditional knockout of Ffar4 exacerbated high-fat diet (HFD)-induced cognitive dysfunction and anxiety, whereas microglial Ffar4 overexpression improved HFD-induced cognitive dysfunction and anxiety. Mechanistically, we found that microglial Ffar4 regulated microglial activation through type I interferon signaling. Microglial depletion and NF-κB inhibition partially reversed cognitive dysfunction and anxiety in microglia-specific Ffar4 knockout MetS mice. Together, these findings uncover a previously unappreciated role of Ffar4 in negatively regulating the NF-κB-IFN-β signaling and provide an attractive therapeutic target for delaying MetS-associated cognitive decline.

Products
Inhibitors & Agonists
Other Products